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Background: Acute myeloid leukaemia (AML) is characterised by the halt in maturation of myeloid progenitor cells,
combined with uncontrolled proliferation and abnormal survival, leading to the accumulation of immature blasts. In
many subtypes of AML the underlying causative genetic insults are not fully described. MicroRNAs are known to be
dysregulated during oncogenesis. Overexpression of miR-155 is associated with some cancers, including haematological
malignancies, and it has been postulated that miR-155 has an oncogenic role. This study investigated the effects of
modulating miR-155 expression in human AML cells, and its mechanism of action.
Results: Analysis of miR-155 expression patterns in AML patients found that Fms-like tyrosine kinase 3 (FLT3)-wildtype
AML has the same expression level as normal bone marrow, with increased expression restricted to AML with the
FLT3-ITD mutation. Induction of apoptosis by cytarabine arabinoside or myelomonocytic differentiation by
1,23-dihydroxyvitaminD3 in FLT3-wildtype AML cells led to upregulated miR-155 expression. Knockdown of miR-155 by
locked nucleic acid antisense oligonucleotides in the FLT3-wildtype AML cells conferred resistance to cytarabine
arabinoside induced apoptosis and suppressed the ability of cells to differentiate.
Ectopic expression of miR-155 in FLT3-wildtype AML cells led to a significant gain of myelomonocytic markers (CD11b,
CD14 and CD15), increase in apoptosis (AnnexinV binding), decrease in cell growth and clonogenic capacity.
In silico target prediction identified a number of putative miR-155 target genes, and the expression changes of key
transcription regulators of myeloid differentiation and apoptosis (MEIS1, GF1, cMYC, JARID2, cJUN, FOS, CTNNB1 and
TRIB2) were confirmed by PCR. Assessment of expression of apoptosis-related proteins demonstrated a marked increase
in cleaved caspase-3 expression confirming activation of the apoptosis cascade.
Conclusions: This study provides evidence for an anti-leukaemic role for miR-155 in human FLT3-wildtype AML, by
inducing cell apoptosis and myelomonocytic differentiation, which is in contrast to its previously hypothesized role as
an oncogene. This highlights the complexity of gene regulation by microRNAs that may have tumour repressor or
oncogenic effects depending on disease context or tissue type.
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Acute myeloid leukaemia (AML) is a heterogeneous dis-
ease, which occurs through the accumulation of mutations
affecting cell growth and differentiation. The sequence of
genetic events leading to disease development remains
largely unknown, and microRNAs are postulated to be key* Correspondence: a.lafferty@amr.org.au
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unless otherwise stated.mediators of leukaemic transformation, particularly in
normal karyotype (NK)-AML [1]. MicroRNAs are short
non-coding RNAs that mediate post-transcriptional con-
trol of gene expression [2]. The silencing of target mRNA
occurs through loading of mature microRNA onto the
RNA-induced silencing complex (RISC), which results in
mRNA cleavage or translational repression. Through their
repressive action, these short 19–25 nucleotide RNA
species are important in numerous processes including
haematopoietic stem cell maintenance [3] and progenitor
self-renewal [4], myeloid differentiation [5], cell cycle and
proliferation [6], apoptosis [7] and gene methylation [8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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21q21.3, in the exon of a long non-coding RNA tran-
script from the B cell integration cluster (BIC) [9], and
encodes for the microRNA miR-155. This microRNA
has emerged as having important roles in haematopoi-
esis, immunity, inflammation and cancer [10-14], and is
the archetypal multifunctional microRNA. In normal
host, miR-155 is upregulated in haematopoietic stem
cells (HSCs), myeloid progenitor cells, granulocytes,
monocytes, macrophages and dendritic cells during
maturation and activation, and is also required for
normal maturation and function of B and T lympho-
cytes [12,13].
MiR-155 was first proposed to be oncogenic after
it was found to be upregulated in diffuse large B cell
lymphoma [9]. Other studies also reported its upregu-
lation in Hodgkin lymphoma [15], chronic lymphoid
leukaemia [16], and AML with FLT3-ITD mutations
[17]. However miR-155 has also been reported to be
downregulated in various haematological malignancies:
Burkitt’s lymphoma [18], CML [19], AML with inv(16)
[20] and 3q26 cytogenetic abnormalities [21], suggesting
that it may play different roles dependent on the type of
malignancy. Contradictory roles for microRNAs are not
unusual due to their ability to inhibit many target genes.
MiR-29 and miR-17-92 cluster, for example, have been
shown to have tumour repressor or oncogenic roles
depending on disease context or tissue type [22,23].
While the mechanism behind the involvement of miR-
155 in B cell lymphoma development has been well stud-
ied in murine models [11], the role of miR-155 in AML
requires further investigation. The strongest experimental
data demonstrating an oncogenic function of miR-155
comes from the overexpression of miR-155 in murine
HSCs that led to the development of a myeloproliferative
disorder without the development of overt AML. How-
ever, these findings have yet to be replicated in a xenograft
model using human HSCs, or recapitulated in in vitro
human HSC cultures [24]. A previous study where miR-
155 was overexpressed in human CD34+ cells reported
that miR-155 decreased the number and size of myeloid
and erythroid colonies [25], but it remains unclear if this
was due to a block in differentiation or miR-155 induced
growth arrest [26]. Hence, the exact role of miR-155 in
human AML remains speculative.
In this study, microRNA expression profiling of nor-
mal karyotpe (NK)-AML [27] confirms that miR-155 is
overexpressed in patients with FLT3-ITD, but not FLT3-
wildtype (WT; which accounts for the majority of NK-
AML patients). It demonstrates through overexpression
and knockdown in vitro studies, that miR-155 has a pro-
apoptotic and pro-differentiation role in FLT3-WT AML
cells, in contrast to its oncogenic function reported in
lymphoma.Results
Expression of miR-155 on normal haematopoietic
progenitors and AML cells
Analysis of microRNA expression by qRT-PCR in NK-
AML samples compared to normal bone marrow found
miR-155 to be significantly overexpressed in patients
exhibiting the FLT3-ITD mutation (4.06- fold increase, p =
0.014), but not FLT3-WT (2.14-fold, p = 0.15) (Figure 1A).
This pattern was recapitulated by AML cell lines
(Figure 1B), where the highest expression was har-
boured by MV4-11 cell line (4.78 ±0.80, mean fold
change relative to OCI-AML3± SEM) which expresses
the FLT3-ITD mutation [28]. The majority of cell lines
tested exhibited similar miR-155 expression patterns to
normal human PBMCs (1.15±0.11, Figure 1B).
To compare miR-155 expression between AML and
normal haematopoietic cells, microRNA expression was
measured in progenitors isolated from human mobilized per-
ipheral blood. Progenitors were sorted into human HSCs
(Lin- CD34+ CD38- CD90+ CD45RA-), MPPs (multipotent
progenitors; Lin-CD34+ CD38- CD90- CD45RA-), CMPs
(common myeloid progenitors; Lin- CD34+ CD38+ CD123+
CD45RA-) and GMPs (granulocyte-macrophage progenitors
(GMPs; Lin- CD34+ CD38+ CD123+ CD45RA+) as de-
scribed previously [29,30]. Analysis of miR-155 expres-
sion in normal haematopoietic progenitors revealed a
trend towards higher expression, similar to that found
in FLT3-ITD AML, in purified HSCs (17.64±11.88,
presented as mean fold change relative to GMP± SEM,
Figure 1C). Expression of miR-155 then appeared to
decrease as cells progressed through MPP (1.517±0.28),
CMP (1.45±0.32) and GMP stages (Figure 1C).
Bioinformatic prediction of miR-155 targets reveals
enrichment for transcription factors that regulate
myeloid cell growth and differentiation
To discover the potential target genes of miR-155, three
bioinformatics databases (TargetScan, microRNA.org and
MicroCosm) were utilised to predict miR-155 3’UTR rec-
ognition elements across the transcriptome of protein
coding genes as described by Bryant et al. [31]. 585 genes
were common to at least two databases and 75 genes were
common to three databases (listed in Additional file 1:
Table S3). Gene ontology (GO) analysis of the permissive
gene target list using DAVID Functional Annotation tool
found an enrichment for genes related to Transcription,
Regulation of Transcription, Myeloid Cell Differentiation,
Apoptosis and Programmed Cell Death amongst others
(Additional file 2: Table S1). From these predicted targets,
genes were selected that may have a role in myeloid
growth, myeloid differentiation and leukaemia develop-
ment as determined by literature searches and GO terms.
The expression levels of 20 genes, putative miR-155
targets as well as key mediators of apoptosis and myeloid
Figure 1 miR-155 expression in AML samples and normal
haematopoietic cells. (A) miR-155 expression levels by qRT-PCR in
normal bone marrow (5 samples) and AML samples with FLT3-ITD
(13 samples) or wildtype (14 samples), values are normalized to the
mean of the normal bone marrow samples (B) miR-155 expression
in selected AML cell lines and PBMCs, presented as mean fold
change + SEM relative to OCI-AML3 (baseline set at 1, white bar).
Unpaired Two Tailed T-Test compared to expression levels in
MV4-11 cells, *p < 0.05, **p < 0.001. n = 3-5 (C) miR-155 expression
levels of haematopoietic progenitor subsets isolated from four
normal mobilized peripheral blood donors, presented as mean + SEM
relative to GMP. No statistical difference detected between groups
using Paired t-test. HSC- haematopoietic stem cell; MPP- multipotent
progenitor; CMP- common myeloid progenitor; GMP- granulocyte
monocyte progenitor.
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mRNA levels of target and pathway related genes were
examined in OCI-AML3 cell line (FLT3-WT AML) trans-
fected with miR-155 or scrambled control for 6, 12, 24
and 48 hours (Figure 2). In OCI-AML3 cells, miR-155 was
found to downregulate the oncogenic genes: MEIS1 (de-
creased by 19.5 ± 5.82% (p < 0.05) at 24 hours), GFI1
(decreased by 24.28 ± 4.56% (p < 0.01) at 48 hours) and
MYC (decreased by 14.12 ± 6.58% (p < 0.05) at 24 hours).
JARID2, part of the polycomb repressive complex, was
downregulated at 24 hours (39.37 ± 8.29%, p < 0.01) and
48 hours (27.65 ± 3.84%, p < 0.05), which itself has many
downstream gene targets. Interestingly, an increase in
the validated miR-155 target genes c-JUN [32] and FOS
[33], which form the AP-1 transcriptional complex, was
detected. c-JUN increased at 48 hours (136.8 ± 31.62%,
p < 0.05) while FOS expression increased at both 24 and
48 hours (121.8 ± 43.46% and 46.03 ± 11.8% respectively,
p < 0.05), suggesting that in this system miR-155 is not
negatively targeting these genes. The presence of an
intermediary gene may explain this positive regulation.
CTNNB1, which codes for β-catenin, was also signifi-
cantly increased at 24 hours (36.99 ± 8.56%, p < 0.05).
TRIB2 a coactivator of the HOXA9/MEIS1 oncogenic
pathway, was increased at 24 hours (89.46 ± 21.60%,
p < 0.01) and 48 hours (44.14 ± 10.70%, p < 0.05). There
were no detectable changes in gene expression of HOXA9,
PBX1, FOXO3, CEBPα, CEBPβ, CCND1, JAK2, ARNTL,
EPAS1, HIF1α, CXCR4 or HDAC4 at any time point (data
not shown).
Altered miR-155 expression results in changes in FLT3-WT
AML cell differentiation
To determine how miR-155 expression affects cell func-
tion, the change in miR-155 expression in differentiation
and apoptosis processes were assessed. It has been previ-
ously reported that during macrophage differentiation
and activation, miR-155 expression increased 60-fold
[10], suggesting that an increase in miR-155 expression
Figure 2 Effects of miR-155 transfection on the expression of selected putative target genes over 48 hours. Assessed by qRT-PCR at 6,
12, 24 and 48 hours after transfection of OCI-AML3 cells with Scrambled control (CTL, grey line) or miR-155 (black line). Results are depicted as
mean fold change in mRNA expression + SEM relative to untreated control cells with baseline set to 1.0 (not shown). β-actin was used as the
reference gene. Statistical significance was assessed using a Paired Two Tailed T-Test. *p < 0.05, **p < 0.01; n = 5-8.
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typical miR-155 expression pattern during monocytic
differentiation and apoptosis, MV4-11 and OCI-AML3
cells were treated with 1,23-dihydroxyvitaminD3 (VitD3,
a known inducer of monocytic phenotype [27]) or cytara-
bine arabinoside (ARAC). OCI-AML3 cells exhibited a
significant increase in miR-155 expression after induction
of apoptosis (3.85 fold, p = 0.019, Figure 3A) and a trend
towards an increase during monocytic differentiation (3.04
fold, Figure 3B). However the FTL3-ITD mutated MV4-
11 cell line exhibited no significant change of miR-155
expression after induction of apoptosis (Additional file 4:
Figure S1A), and a trend towards decrease in miR-155
expression during induction of monocytic differentiation
at 48 hours after VitD3 treatment (p = 0.1513, Additional
file 4: Figure S1B).
To determine if modulating miR-155 expression could
impact monocytic differentiation of FLT3-WT AML
cells, OCI-AML3 cells were transfected with synthetic
miR-155 or anti-miR-155 LNA (and matched scrambled
controls), in the presence or absence of VitD3. Analysis
of OCI-AML3 phenotype using CD11b (myeloid) and
CD14 (monocyte) markers (Figure 3C), found that ec-
topic expression miR-155 induced a significant 2.48-fold
increase in cells positive for both CD11b and CD14 after
48 hours, which was not further increased by VitD3
treatment (1.71-fold increase compared to Scrambledcontrol, Figure 3D). miR-155 overexpression also in-
duced an increase in CD15 (granulocyte marker) positive
cells at 48 hours (Figure 3F).
Conversely, miR-155 inhibition by anti-miR-155 in
OCI-AML3 cells decreased the monocytic differentiation
potential of the cells upon VitD3 treatment by 13.42%
(p = 0.0324, Figure 3E), but had no significant effect on
the phenotype of unstimulated cells. MiR-155 knock-
down also decreased the proportion of CD15 positive
cells and inhibited the gain of CD15 upon VitD3 treat-
ment (Figure 3G). Transfection of FLT3–ITD mutated
MV4-11 cells with anti-miR-155 failed to demonstrate sig-
nificant differences in proportion of CD11b and CD14
positive cells, even after treatment with VitD3 (p = 0.2718
without VitD3 induction, and p = 0.1761 with VitD3 in-
duction, Additional file 5: Figure S2A).
miR-155 expression can regulate AML cell survival
To assess the effects of miR-155 expression in AML cell
survival, the human cell lines OCI-AML3 (AML- M4),
THP1 (AML- M5), NB4 (AML- M3), HL60 (AML- M2)
and MV4-11 (AML- M4) were used. Cells were trans-
fected with synthetic miR-155 or scrambled control and
assayed with annexinV, a marker of early apoptosis, and
7-AAD, a marker of late apoptosis, at varying time
points (Figure 4). In OCI-AML3 cells, a strong increase
in annexinV binding was detected at 24, 48 and 72 hours
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Figure 3 miR-155 expression levels affect myeloid differentiation of AML cells. Expression of miR-155 48 hours after (A) ARAC induced
apoptosis of OCI-AML3 cells or (B) VitD3 induced monocytic differentiation of OCI-AML3 cells. Data is presented as mean fold change expression
of miR-155 + SEM relative to Untreated control; RNU6b was used as the reference gene, n = 3. VitD3 was used to induce myeloid differentiation in
OCI-AML cells transfected with miR-155, anti-miR-155 or their respective controls (C) flow cytometry plots of phenotype analysis using CD11b and
CD14 (D) miR-155 overexpression increased the percentage of CD11b + CD14+ cells at 48 hours (E) percentage expression of CD14 + CD11b + cells
transfected with anti-miR155 and exposed to VitD3 (+) or PBS (−) for 48 hours (F)miR-155 overexpression increased the percentage of cells expressing
CD15 at 48 hours without VitD3 stimulation (G) miR-155 inhibition decreased the percentage of cells expressing CD15. CTL- scrambled control;
ARAC- cytarabine arabinoside; VitD3- 1,23-dihydroxyvitaminD3. Statistical significance determined using Paired Two Tailed t-Test, *p < 0.05; n = 4.




















































3.15±0.38 0.0258 4.11±0. 26 0.0020
THP1 1.39±0.08 0.0079 1.31±0.06 0.0053
NB4 1.47±0.36 0.4431 1.09±0.15 0.5865
HL60 1.44±0.12 0.0446 1.22±0.07 0.0729
MV4-11 0.96±0.01 0.1123 1.21±0.08 0.1166
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Figure 4 Induction of apoptosis of OCI-AML3 cells after miR-155 transfection. (A) Gating strategy for flow cytometry analysis. Cells undergoing
early apoptosis are stained for AnnexinV, cells undergoing late apoptosis are stained for both AnnexinV and 7-AAD (B) increase in AnnexinV positive cells
(dashed line) or Double Positive cells for AnnexinV/7-AAD (solid line) post transfection with miR-155 (black line) compared to CTL (grey line) (C) summary
of fold-change of cells (OCI-AML3, THP1, NB4, HL60, MV4-11) binding AnnexinV overexpressing miR-155 normalised to CTL at 24 and 48 hours
post transfection. AnnV + AnnexinV positive cells; DP- double positive cells, CTL- Scrambled control. Statistical significance determined using
Paired Two Tailed t-Test, *p < 0.05 of AnnV + cells; +p < 0.05 of DP cells, n = 4-7.
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followed by an increase in annexinV/7AAD double
positive cells at 48 and 72 hours (Figure 4A, B). This
latency in the gain of 7AAD staining reflects the passage
of cell through the early apoptotic stages, to cell necro-
sis. The THP1 cell line also demonstrated significantly
increased apoptosis with miR-155 overexpression, with
1.39±0.08 and 1.31±0.06 fold increase in annexinV posi-
tive cells compared to scrambled control at 24 and
48 hours respectively. HL60 cells demonstrate a signifi-
cant increase in annexinV binding at 24 hours, which
was attenuated at 48 hours. While the NB4 cell line
demonstrated a trend towards an increase at 24 hours
(1.47±0.36), but this was not significant. The survival ofA B
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Figure 5 Growth perturbations in AML cells with altered miR-155 exp
in a reduction of cell growth at 24 h and 48 h as determined by MTS assay (B
colony number and (C) a trend towards reduced colony size (presented as m
did not demonstrate a significant change (E) Cell cycle analysis demonstrated
miR-155 overexpression. CTL, Scrambled Control (F) Transfection of OCI-AML3
proportion of cells undergoing apoptosis (AnnexinV+) when treated with ARA
nucleic acid; CTL, Anti-Scrambled LNA. Statistical significance determined usinMV4-11 cells was not significantly affected by an in-
crease in miR-155 levels (Figure 4C).
The pro-apoptotic role of miR-155 was further supported
by MTS assay of OCI-AML3 cells overexpressing miR-155
or scrambled control, which demonstrated a significant
reduction in cell number at 24 and 48 hours (41.7%
(p = 0.017) and 66.8% (p = 0.048) respectively, Figure 5A).
Assessment of the clonogenic potential of cells overex-
pressing miR-155 or control by growth in semi-solid
media (Figure 5B), demonstrated a reduction in colony
formation by miR-155 overexpressing cells (147±19
colonies per 35 mm dish versus 282±14 colonies of
control cells, p = 0.027), with a concurrent trend to-
wards smaller colony size (487±130 vs 681±262 cellsC
F
y Number Colony Size
raction Apoptosis with miR-
155 inhibition
ression levels. (A) Transfection of OCI-AML3 cells with miR-155 resulted
) Assessment of colony forming potential found a decrease in mean
ean + SEM cells per colony) (D) Proliferation through BrdU incorporation
an increase in the proportion of cells in the SubG1 fraction at 48 h post
cells with anti-miR155 LNA resulted in a significant decrease in the
C, but not when untreated. ARAC-cytarabine arabinoside; LNA-locked
g Paired Two Tailed t-Test, *p < 0.05 ** p < 0.001; n = 3-4.
Table 1 miR-155 overexpression induces changes in










Cleaved caspase 3 2.5 0.21
Clusterin 1.8 0.24












phospho-p53 (S15) 1.33 0.42
phospho-p53 (S392) 1.6 0.68
phospho-p53 (S46) 1.8 0.8
phospho-p53 (S635) 1.5 0.42
PON2 0.88 0.24
Pro-caspase 3 1.72 0.61
SMAC, Diablo 1.37 0.1
Survivin 1.24 0.22
TNFRI/TNFRSF1A 1.25 0.22
TRAIL R1/DR4 0.76 0.13
TRAIL R1/DR5 0.8 0.06
XIAP 2 0.44
Apoptosis array results indicating mean fold-change (with SEM, n = 3) of
apoptosis related proteins between Scramble control and miR-155 transfected
cells.
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oration (not shown) or BrdU (Figure 5D) uptake did
not demonstrate a significant change in the proportion
of cells in G1, S or G2/M phases. Both assays however
did detect a significant increase in the number of cells
in the Sub-G1 fraction (3.04-fold increase at 48 hours,
p = 0.0025, Figure 5E), further supporting an induction
of cell death by miR-155 overexpression.
To support this finding, miR-155 expression was
inhibited in OCI-AML3 and MV4-11 cells using anti-
miR-155 LNA or Scrambled LNA control, and apoptosis
levels were assessed by annexinV/7AAD binding assay.
OCI-AML3 cells exhibited significantly less apoptosis
upon treatment with ARAC than control cells (33.82±
2.72% annexinV binding in anti-miR-155 cells versus
40.93±2.58% in control cells, p = 0.0007, Figure 5F), sug-
gesting that inhibiting miR-155 levels protects cells from
cell death inducers like ARAC. Apoptosis levels of un-
treated OCI-AML3 (Figure 5F) or MV4-11 (Additional
file 5: Figure S2B) cells were not changed by miR-155
knockdown.
Increased expression of miR-155 activates the apoptosis
cascade in AML cells
To identify the apoptotic mechanisms responsible for
the increase in cell death caused by miR-155 overexpres-
sion, the levels of apoptotic proteins were profiled by the
R&D Systems Proteome Profiler Apoptosis Array in
OCI-AML3 cells transfected with synthetic miR-155 or
Scrambled control, in three independent repeats. The
Antibody Array demonstrated trends towards increased
expression of pro-apoptotic proteins (p27/kip1, BAD,
FAS, Procaspase-3, Cleaved Caspase 3, phosphorylated
p53, OMI/HTRA2) and anti-apoptotic proteins (XIAP,
BCL-X, HSP32, Clusterin) with at least a 1.5-fold in-
crease in expression in miR-155 overexpressing cells
compared to control (Table 1).
We confirmed that apoptosis was occurring through
caspase-3 activation, by probing for cleaved caspase-3
expression by flow cytometry (Figure 6). Results show
that caspase-3 activation is increased 2.73-fold (p < 0.05)
and 4.19-fold (p < 0.01) at 24 and 48 hours (respectively)
after miR-155 transfection compared to scrambled con-
trol, demonstrating that high miR-155 expression induces
apoptosis in these cells through caspase activation.
Discussion
MiR-155 has been linked to the development of haem-
atopoietic malignancies, however it remains a critical
part of normal development, with its expression essential
for haematopoietic cell maturation, immune cell differ-
entiation and function. It also has established roles in
maintaining homeostatic regulatory loops in the immune
system. Within the context of AML development, miR-155 has been cited as oncogenic, with increased expres-
sion in AML with the FLT3-ITD mutation, and recently,
its correlation with poor survival in subsets of older
patients [34]. Our study demonstrated pro-apoptotic and
pro-differentiation functions for miR-155, hence an anti-
leukaemia role in AML, highlighting the complexity of
microRNA based regulation and challenging our current








































Figure 6 Effect of miR-155 overexpression on the expression of Cleaved Caspase-3. Cleaved caspase-3 expression was confirmed to be
upregulated in miR-155 transfected cells by a flow cytometry based assay (A) flow plots of activated caspase-3 in miR-155 overexpressing or CTL
cells at 24 h and 48 h (B) significant increase in the percentage of cells expressing activated caspase-3. Statistical significance determined using
Paired Two Tailed t-Test, *p < 0.05, **p < 0.01; n = 4.
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ment and malignancy.
In this study we showed that AML patients with
FLT3-ITD mutation express a higher level of miR-155
than FLT3-WT patients or normal controls. This supports
the finding of Garzon et al. [35] who reported a ~5-fold
increase in FLT3-ITD AML patients. They further demon-
strated that miR-155 expression is independent of FLT3-
ITD signal. In our study, AML cell lines recapitulated this
expression pattern, with MV4-11 cells expressing the
highest miR-155 level compared to FLT3-WT cell lines
(NB4, THP1, OCI-AML and HL60). FLT3-WT cell lines
expressed similar levels of miR-155 to normal human
PBMCs.
Gene target prediction was used as a preliminary indica-
tor of miR-155 function. Bioinformatic prediction followed
by GO analysis using the DAVID Annotation Tool yielded
a set of target genes which focused heavily on transcrip-
tional modulators, as well as myeloid differentiation genes
and apoptosis regulators (Additional file 2: Table S1).
qRT-PCR analysis for a set of 20 genes provided evidence
of potential functions for miR-155 in AML cells. We
observed the upregulation of miR-155 during inducedapoptosis and monocytic differentiation in FLT3-WT
AML, suggesting its involvement in these processes.
Our experimental data support a role for miR-155 in
the AML maturation block, with its overexpression
inducing the expression of CD11b, CD14 and CD15 sur-
face markers in over 70% of cells. This phenotype is con-
sistent with cells released from differentiation block [36].
Further, knockdown of miR-155 in these cells decreased
their ability to differentiate upon stimulation with VitD3.
This ability of miR-155 to induce maturation is consist-
ent with its postulated role in myeloid cell lineage com-
mitment from HSCs and myeloid progenitors. MiR-155
expression is required for the differentiation of myeloid
cells into functional macrophages [10,37] and dendritic
cells [38], and myeloid differentiation of murine HSCs
in colony forming assays [25]. This pro-differentiation
function of miR-155 is supported by its involvement in
key genetic networks in haematopoietic differentiation.
PU.1, a master haematopoietic transcription factor, a
target of miR-155, is necessary for myeloid differenti-
ation of HSCs [39], while AP-1 and NF-κB transcription
factors are postulated to regulate miR-155 expression in
macrophages [10].
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pathway analysis and validation by qRT-PCR revealed
that miR-155 expression positively correlates with the
expression of the AP-1 genes c-JUN and FOS, which are
known to induce myeloid differentiation [40]. They were
also detected upon the release of the AML maturation
block in this study. MiR −155 expression was found to
downregulate the oncogenic MEIS1 and GFI1 genes,
which work in synergy with HOXA9 to accelerate AML
transformation [41]. Normally GFI1 functions as a key
regulator of HSC and neutrophil development, and its
upregulation is leukaemogenic [42]. MEIS1 is oncogenic
in murine bone marrow through the activation of TRIB2,
which in turn inhibits C/EBPα, halting myeloid differenti-
ation [43]. We detected no change in C/EBPα expression,
suggesting that the induction of myeloid maturation is
occurring through an alternate pathway. JARID2 is a con-
firmed target of miR-155 by luciferase assay [44] and is
downregulated by miR-155 overexpression in this study.
JARID2 is a co-activator and recruiter of the Polycomb re-
pressive complex 2 (PRC2) responsible for the repression
of a wide range of target genes [45].
Together with an induction of myeloid maturation, the
overexpression of miR-155 was found to induce apop-
tosis in OCI-AML3, THP1 and HL60 cell lines as de-
tected by AnnexinV/7AAD assay. The strong apoptotic
response seen in the OCI-AML3 cells were confirmed
by MTS assay and the increased sub-G1 cell population.
This finding supports previous observations of increased
sub-G1 population and partial differentiation of THP1
cells [26], and induction of apoptosis in dendritic cells [38]
upon miR-155 overexpression. Importantly, our study also
demonstrated that knockdown of miR-155 conferred
protection from chemotherapy insult. In tumor clono-
genic assays miR-155 overexpression resulted in de-
creased colony number and size. This supports the
study by Georgantas et al., where miR-155 overexpres-
sion in normal human CD34+ cells generated fewer
and smaller myeloid and erythroid colonies [25].
We found overexpression of miR-155 led to increase
in cJUN, FOS and TRIB2, and decrease in MEIS1, GFI1,
cMYC and JARID2. Induction of AP-1 transcription factors
have been reported to result in increased phosphorylation
activity of JNK and activation of caspase-3 dependent
apoptosis in AML [46,47]. Decrease in MEIS1, GFI1 and
cMYC, has been shown to inhibit tumour cell growth, and
an increase in TRIB2 may be pro-apoptotic [48]. Our study
demonstrates that miR-155 induces apoptosis through
a caspase-3 mediated mechanism. This increase in
cleaved caspase-3 was accompanied by a trend towards
increased levels of pro-apoptotic p27/kip1, BAD, pro
caspase-3, phosphorylated p53, FAS and HSP32 as well
as increased levels of the anti-apoptotic XIAP, BCL-XL
and CLUSTERIN. We postulate that miR-155 inducesapoptosis via a combination of p53 activation, p27/kip
induction via downregulation of cMYC [49], phosphor-
ylation of JNK by increased AP-1 or TRIB2 expression,
or regulation of cyclinD1 by JARID2 downregulation
[50] (Figure 7).
MiR-155 has been postulated as oncogenic [9,11,24],
however our findings show induction of apoptosis and dif-
ferentiation upon miR-155 overexpression in AML cells.
There are a number of plausible explanations for this dual
effect. Firstly, miR-155 may have different targets in differ-
ent subtypes of AML as reported for microRNA-17-92 in
different B-cell lymphoma subtypes [51]. Secondly, miR-
155 could target both oncogenes and tumour suppressors
to varying degrees within the same cells as reported for
miR-196b [52], and might favour one over the other in
particular subtypes of AML. Thirdly, miR-155 may have
different functions depending on its expression level. At
functionally high but transient levels of miR-155, such as
during the immune response, cells are physiologically nor-
mal, however, at prolonged intermediately high levels
miR-155 appears to be oncogenic [14]. This could be due
to escaping of feedback inhibitory loops, targeting of dif-
ferent transcripts or dose-dependent effects that different
miR-155 levels may have on the same transcripts.
We acknowledge that the strength of the conclusions
of this study are hampered as they are based on in vitro
experiments and clinical observational studies. The func-
tional role of miR-155 should be further studied using
animal models and primary AML samples to elucidate
the role of miR-155 in the distinct molecular networks
within this heterogeneous disease. Comprehensive studies
of miR-155 gene targets (using HITS-CLIP for example)
in AML are required. However, our study adds to an
increasing pool of evidence [19,26] that miR-155 has an
anti-tumour function and is not only pro-tumourigenic.
In a recent study Marcucci et al. [34] reported that
higher miR-155 expression levels had a negative impact
on the outcome of AML in patients, most markedly in
younger patients. Although this is a significant study
and provides an important novel outcome marker for
AML in younger patients, it does not help clarify the
biological actions of miR-155. In support of our findings,
microarray transcriptome analysis of AML patients
found the strong positive correlations between miR-155
expression and pro-apoptosis genes (GO:0006915-Apop-
tosis) and haematopoietic pro-differentiation genes, as
well as anti-apoptosis genes, suggesting that miR-155 is
inducing expression of anti-tumour and pro-tumour
genes in the same cohort.
In lung cancer, contrary the report by Marcucci et al.,
low miR-155 expression correlates with aggressive disease
with increased occurrence of metastases [53], similarly in
breast cancer where a lack of miR-155 expression links






















Figure 7 Potential regulatory mechanisms of miR-155 in AML. Model of miR-155-mediated gene regulation in FLT3-WT AML, where its
expression acts to induce myeloid differentiation and caspase-3 dependent apoptosis. In AML cells miR-155 overexpression was found to decrease
the expression of cMYC and MEIS1/GFI1, potentially leading to the phosphorylation of JNK and/or the activation of p27/kip1 and activation of the
apoptosis cascade. The increase in AP-1 and TRIB2 genes may be caused by an intermediary, such as JARID2 inhibition, and may have functions in
regulating AML cell differentiation and apoptosis.
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miR-155 expression can correlate with significantly longer
OS in patients with prostate or high-risk breast cancer
(Additional file 6: Figure S3). In summary, these clinical
studies lend support to our finding that miR-155 can have
ant-tumour functions.
Conclusions
This study provides novel evidence for an anti-
leukaemia function of miR-155 in AML by inducing cell
apoptosis through caspase-3 activation, and releasing the
myeloid differentiation block. Overexpression of miR-
155 was found to alter the expression of transcription
factors and chromatin modifiers that regulate myeloid
cell survival and differentiation, and upregulate media-
tors of the apoptotic cascade. The precise downstream
pathways targeted by miR-155 remain to be elucidated.
Our study provides evidence that the gene regulation
by miR-155 is complex, as it targets both tumoursuppressors and oncogenes, and its function in a spe-
cific malignancy is likely subject to disease context and
cell type.
Materials and methods
Cell lines and patient samples
This study was reviewed and approved by The St Vincent's
Hospital Human Ethics Committee (HREC 06/064). Cell
lines OCI-AML3 and HL60 cells purchased from the
DSMZ cell-line bank (Braunschweig, Germany), and MV4-
11, NB4 and THP1 cells were purchased from ATCC
(Virginia, USA). Isolation of haematopoietic progenitors
was performed on donated mobilized peripheral blood
product. Diagnostic bone marrow samples of 27 NK-
AML cases with leukemic blast counts of at least 50%
were obtained after informed consent from the tissue
banks of our institute and the Australian Leukaemia
and Lymphoma Group Tissue Bank. Five normal bone
marrow samples were obtained from our institute’s
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as described in [31]. To determine FLT3 mutational status,
the insertional hotspot was RT-PCR amplified from com-
plementary DNA using previously described primers [31]
and directly sequenced on the 3100XL from ABI 3100XL
Genetic Analyser. 13/27 (48.1%) samples harboured a
mutation in the FLT3 gene.
To confirm miR-155 expression in primary samples
and comparison of expression in cell lines, 1 μg of total
RNA was used for cDNA synthesis reaction using the
NCode microRNA first strand synthesis kit (Invitrogen,
USA). Quantitative real time polymerase chain reaction
(qRT-PCR) was performed using the Platinum SYBR
Green qPCR SuperMix-UDG (Life Technologies, USA)
and the Rotorgene RG-3000 thermocycler (Qiagen, Hilden,
Germany). RNU6b and RNU43 were used as the reference
genes (primer sequences in Additional file 7: Table S4). For
functional cell line work, microRNA expression was quanti-
fied by the TaqMan miRNA assay (Applied Biosystems) as
per manufacturer’s instructions. All qPCR reactions were
performed in duplicate and RNU6b was used as the refer-
ence gene. MicroRNA expression data are expressed as
mean fold change in gene expression (+SEM) relative to
control. Two-tailed T-tests were performed on ΔCt values
to determine significant differences (defined as p < 0.05) be-
tween two groups.
Fluorescence-activated cell sorting (FACS) of human
haematopoietic progenitors
Mobilised peripheral blood samples were thawed, washed
in PBS and incubated at 37°C with PBS/1% FBS/1 mM
EDTA (FACS Buffer) for 30 mins and non-adherent
cells collected to remove monocytes. Lineage-negative
cells were collected by using EasySep® Human Progenitor
Cell Enrichment Kit (STEMCELL Technologies, Victoria,
Australia). Cells were incubated with EasySep® Enrichment
Cocktail followed by EasySep® Magnetic Nanoparticles.
Cells were then incubated for 10 mins in the EasySep®
magnet, where lineage-negative cells were magnetically
separated. Lineage-negative cells were stained with the
following fluorophore-conjugated antibodies: Lineage-
FITC, CD34-phycoerythrin (PE)Cy7, CD38-PerCP-Cy5.5,
CD45RA-PacificBlue, CD90-APC, CD123-PE (BD Biosci-
ences, San Jose, CA, USA). Cells were FACS sorted and
analyzed using BD Influx Cell Sorter (BD Biosciences,
San Jose, CA, USA). Cells were collected in sterile FACS
buffer, and stored at −80°C in QIAzol (Qiagen, Valencia,
CA, USA) until RNA extraction.
miR-155 target prediction and pathway analysis
Three bioinformatic databases were used for the in silico
prediction of miR-155 targets: TargetScan [58], micro-
RNA.org [59,60] and MicroCosm [61]. Predicted target
genes were obtained that were common to at least 2 ofthe 3 databases or 3 of the 3 databases (accessed on 27/
7/2012). Selected target genes were chosen for qRT-PCR
analysis based on their putative involvement in AML
development. The DAVID Functional Annotation Tool
(http://david.abcc.ncifcrf.gov/summary.jsp) was used to
classify the genes into ontologically-related terms and
then examine for enriched terms [62].
RNA was extracted from cell samples using TRizol
(Life Technologies) according to the manufacturers in-
structions. 1 μg of total RNA was used in the cDNA syn-
thesis reaction using SuperScriptIII reverse transcription
kit (Life Technologies). qRT-PCR was performed using the
Platinum SYBR Green qPCR SuperMix-UDG on a Rotor-
Gene 3000. Data were analysed using the ΔΔCT method.
β-Actin was found to be stably expressed in these experi-
ments, and was thus used as the reference gene. Primers
are listed in Additional file 7: Table S4. Gene expression
data were expressed as mean fold change in gene expres-
sion (+SEM) relative to control. t-tests were performed to
determine significant differences defined as p < 0.05.
miR-155 overexpression and antisense repression
Cell lines were cultured in RPMI or α-MEM solution
with 10% fetal bovine serum (GIBCO). Cells were trans-
fected with 50 nM pre-miR-155 (Ambion) or anti-miR155
miRCURY LNA™ microRNA knockdown probes (Exiqon,
Denmark) or appropriate scrambled control using Lipo-
fectamine 2000 and Opti-MEM (both from LifeTechnolo-
gies, USA) in antibiotic-free media. Lipofectamine based
transfection was found to cause on average 3.6% cell
death. Cells were maintained in a humidified incubator at
37°C in 5% CO2. miR-155 overexpression and knockdown
was confirmed by TaqMan qRT-PCR as per manufac-
turer’s instructions (Applied Biosystems).
Functional assays
Cell growth was analysed at 24 and 48 hours using the
Promega CellTiter Aqueous One Solution cell Proliferation
Assay (Promega) according to the manufacturer’s instruc-
tions, using Multiskan plate reader (Thermo Labsystems).
For this assay cells were plated in triplicate for each trans-
fection condition and time point. The MTS absorbance
reading at each time point was normalised to a non-
transfected lipofectamine-only control.
Clonogenicity of cells treated with pre-miR-155 or
scrambled control was assayed by seeding 400 cells in
1 mL 1% MethoCell MC (in RPMI with 10% FBS per
35 mm plate). Colony number and size were scored
microscopically (colony defined as >50 cells) using stand-
ard criteria after 14 days at 37°C in 5% CO2.
Cell cycle analysis was performed by exposing cells to
1 mL 1% TX-100, 50 μL 50 mg/mL propidium iodide (PI)
and 50 μL of 10 mg/mL RNAaseA at 37°C for 30 minutes
and analysed by flow cytometry. Analysis of proliferation
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deoxyuridine) for 45 mins, before fixing with absolute
ethanol and probing using a primary mouse-anti-BrdU
antibody (BD Biosciences) and goat-anti-mouse-APC
conjugated secondary antibody (Jackson Laboratories,
Pennsylvania, USA). Cells were co-stained with 1 mg/
mL PI and treated with 0.5 mg/mL RNAse before flow
cytometry analysis. Apoptotic fractions cells were ana-
lysed by Annexin V/7-AAD staining using the Annexin
V-APC Apoptosis Detection Kit I (BD Pharminogen)
according to the manufacturer’s instructions. Intracellular
activated caspase-3 was directly measured by staining
permeabilised cells (FACSperm, BD Biosciences) with PE
Rabbit Anti-Active Caspase-3 (BD Pharmingen). Data
collection for these assays was performed using a LSRII
flow cytometer (Becton Dickinson, Mountain View, CA),
and analysis was performed on FlowJo Software on at least
10,000 acquired events.
Induction of monocytic differentiation of AML cells
Monocyte differentiation was induced by a 48 hour pulse of
10nM 1,23-dihydroxy-vitaminD3 (Sigma-Aldrich, St Louis,
MO). Cells were collected at 0 and 48 hours for total RNA
extraction and cell characterization. Cell lineage-specific
marker expression was analyzed by flow cytometry in
untreated and treated cells at various time points during
differentiation. Flow cytometry analysis was performed
using CD14-FITC, CD15-PE and CD11b-APC, together
with their respective isotype controls (all from BD Phar-
migen, San Jose, CA). Cells were incubated with 10uL
of a specific antibody or antibody combination and were
incubated in the dark for 20 min at room temperature.
Cells were washed twice with PBS containing 0.5%
bovine serum albumin and 0.1% Sodium Azide and resus-
pended in 0.5% paraformaldehyde. Cells were analyzed
immediately by LSRII flow cytometer with a minimum
acquisition of 30,000 events.
Antibody array methods
Proteome Profiler Human Apoptosis Array Kits from
R&D Systems were used to measure levels of apoptosis
related proteins according to the manufacturer’s protocol.
200ug of protein was applied per array. In this method,
proteins are captured by antibodies spotted on a nitrocel-
lulose membrane, then levels of protein expression are
assessed using a HRP-conjugated antibody, followed by
chemiluminesce detection. This was analysed using the
QuantityOne Software.
Additional files
Additional file 1: Table S3. Potential targets of miR-155 predicted by
each of MicroCosm, microRNA.org and TargetScan. 72 genes were
commonly predicted to be targeted by miR-155 by the three algorithms.Additional file 2: Table S1. Gene Ontology terms enriched in predicted
miR-155 targets. Gene ontology analysis was performed using DAVID
Functional Annotation Tool, using the permissive 585-gene list which
included putative miR-155 targets predicted by two of three bioinformatics
databases (TargetScan, microRNA.org, MicroCosm).
Additional file 3: Table S2. List of potential miR-155 target genes
analysed [24, 25,41,42,44,63-66].
Additional file 4: Figure S1. miR-155 expression levels during MV4-11
cell apoptosis and monocytic differentiation. Expression of miR-155 during
(A) ARAC induced apoptosis of MV4-11 cells or (B) VitD3 induced monocytic
differentiation of MV4-11 cells. Data is presented as mean fold change
expression of miR-155 + SEM relative to untreated control; RNU6b was
used as the reference gene. Paired Two Tailed T-Test did not detect
significant differences; n = 3.
Additional file 5: Figure S2. Functional effects of miR-155 knockdown
in MV4-11 cells. (A) VitD3 was used to induce myeloid differentiation in
MV4-11 cells transfected with anti-miR155 LNA or CTL. Percentage expression
of CD14 + CD11b + cells transfected with anti-miR155 and exposed to VitD3
(+) or PBS (−) for 48 hours did not demonstrate significant difference with
miR-155 inhibition (B) Transfection of MV4-11 cells with anti-miR155 LNA
did not result in a change in the proportion of cells undergoing apoptosis
(AnnexinV+). LNA- locked nucleic acid. Statistical significance determined
using Paired Two Tailed T-Test; n = 3.
Additional file 6: Figure S3. Kaplan-Meier survival analysis demonstrating
increased overall survival in patients with miR-155 overexpressing tumours.
(A) Assessment of microRNA expression from 218 patients with primary or
metastatic prostate cancer with a median of 5 years clinical follow-up,
demonstrate higher survival probability in patients with higher miR-155
expression, p = 0.0155 [56] (B) expression profiling of 38 high-risk ER +
breast cancers demonstrate higher OS in patients with high miR-155
expression, p = 0.000121 [55].
Additional file 7: Table S4. List of primer sequences. All mRNA primers
were designed to be intron spanning.
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